Innate Pharma (IPHYF) Total Liabilities (2017 - 2019)

Innate Pharma's Total Liabilities history spans 3 years, with the latest figure at $203.6 million for Q4 2019.

  • For Q4 2019, Total Liabilities fell 37.18% year-over-year to $203.6 million; the TTM value through Dec 2019 reached $203.6 million, down 37.18%, while the annual FY2019 figure was $203.6 million, 37.18% down from the prior year.
  • Total Liabilities reached $203.6 million in Q4 2019 per IPHYF's latest filing, down from $324.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $324.1 million in Q4 2018 to a low of $199.1 million in Q4 2017.
  • Average Total Liabilities over 3 years is $242.3 million, with a median of $203.6 million recorded in 2019.
  • Peak YoY movement for Total Liabilities: surged 62.83% in 2018, then plummeted 37.18% in 2019.
  • A 3-year view of Total Liabilities shows it stood at $199.1 million in 2017, then soared by 62.83% to $324.1 million in 2018, then crashed by 37.18% to $203.6 million in 2019.
  • Per Business Quant, the three most recent readings for IPHYF's Total Liabilities are $203.6 million (Q4 2019), $324.1 million (Q4 2018), and $199.1 million (Q4 2017).